Artemis Therapeutics Inc.
ATMS · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 82.6% | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $0 | $0 | $0 |
| Operating Income | -$1 | -$0 | -$0 | -$0 |
| % Margin | -437% | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | $0 | -$0 | -$0 |
| Net Income | -$1 | -$0 | -$0 | -$0 |
| % Margin | -434.4% | – | – | – |
| EPS | -0.01 | -0.007 | -0.024 | -0.024 |
| % Growth | -44.9% | 70.6% | 0% | – |
| EPS Diluted | -0.01 | -0.007 | -0.024 | -0.024 |
| Weighted Avg Shares Out | 57,058 | 26 | 5 | 5 |
| Weighted Avg Shares Out Dil | 57,058 | 26 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$0 | -$0 | -$0 |
| % Margin | -431.8% | – | – | – |